GEN Exclusives

More »

GEN News Highlights

More »
May 6, 2010

Endo Acquires HealthTronics for $223M

Endo Acquires HealthTronics for $223M

Firm claims strategic acquisition will transform it from pharma company to diversified physician partner.

  • Endo Pharmaceuticals is buying urological products and services firm HealthTronics for $223 million in cash plus the assumption of around $35 million in debt. Endo said the acquisition will provide it with new urology products including benign prostatic hyperplasia and prostate cancer therapies, as well as lithotripsy and anatomical pathology services for the diagnosis and detection of cancer and other diseases.

    Endo focuses on the research, development, sale, and marketing of branded and generic prescription pharmaceuticals for the treatment and management of pain, bladder cancer, prostate cancer, and the early onset of puberty in children.

    The firm said that acquiring HealthTronics will diversify its revenue base and boost its position as a provider of multiple medical solutions and delivery mechanisms in urology. “This strategic acquisition immediately elevates Endo from a pharmaceutical company to a diversified partner to physicians and payers in the treatment and diagnosis of urological and pain-related conditions,” stated Dave Holveck, president and CEO.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?